[
  {
    "ts": null,
    "headline": "Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock",
    "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
    "url": "https://finnhub.io/api/news?id=a899efd51df4b05fedf01af23e328c2b9ed982cb3146e2aa0d13108681303547",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764600002,
      "headline": "Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock",
      "id": 137659365,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.",
      "url": "https://finnhub.io/api/news?id=a899efd51df4b05fedf01af23e328c2b9ed982cb3146e2aa0d13108681303547"
    }
  },
  {
    "ts": null,
    "headline": "Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO",
    "summary": "SOUTH SAN FRANCISCO, Calif., December 01, 2025--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer. Soleymannezhad, formerly Chief Commercial Officer at MaxCyte (NASDAQ: MXCT) and Executive Vice President at Tosoh Bioscience, will lead global commercial strategy as the company deploys its network of IDMO Smart Factories across the United States, Europe, and Japan. Soleymannezhad’s app",
    "url": "https://finnhub.io/api/news?id=5c4c48bb36bcf3b60a84b7bce07e4e7210fb0c5839f0932e239710787ae3b75a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764597600,
      "headline": "Cellares Appoints Former MaxCyte Commercial Chief Ali Soleymannezhad as Chief Commercial Officer to Lead Global IDMO Expansion, Catalyze Next Wave of Partnerships, Prepare for IPO",
      "id": 137659366,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "SOUTH SAN FRANCISCO, Calif., December 01, 2025--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced the appointment of Ali Soleymannezhad as Chief Commercial Officer. Soleymannezhad, formerly Chief Commercial Officer at MaxCyte (NASDAQ: MXCT) and Executive Vice President at Tosoh Bioscience, will lead global commercial strategy as the company deploys its network of IDMO Smart Factories across the United States, Europe, and Japan. Soleymannezhad’s app",
      "url": "https://finnhub.io/api/news?id=5c4c48bb36bcf3b60a84b7bce07e4e7210fb0c5839f0932e239710787ae3b75a"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio",
    "summary": "PRINCETON, N.J., December 01, 2025--Bristol Myers Squibb Data at ASH 2025 Showcases Potential of Hematology Pipeline and Builds Momentum for Next Generation Portfolio",
    "url": "https://finnhub.io/api/news?id=4cbbbf9ad235d174b770d7a909f74e063588f8ddcf9931e0e7f1b43174533222",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764590340,
      "headline": "Bristol Myers Squibb Data at ASH 2025 Showcase Potential of Hematology Pipeline and Build Momentum for Next Generation Portfolio",
      "id": 137659367,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "PRINCETON, N.J., December 01, 2025--Bristol Myers Squibb Data at ASH 2025 Showcases Potential of Hematology Pipeline and Builds Momentum for Next Generation Portfolio",
      "url": "https://finnhub.io/api/news?id=4cbbbf9ad235d174b770d7a909f74e063588f8ddcf9931e0e7f1b43174533222"
    }
  },
  {
    "ts": null,
    "headline": "2 Undervalued, High-Quality Companies to Buy Now and Hold Forever",
    "summary": "If you are looking to own a stock for the long term, these out-of-favor drugmakers have proven they have what it takes to survive.",
    "url": "https://finnhub.io/api/news?id=15560fee524920002e1518664dcc0ea6c8ab46fe1c923913fd80fd84f81ec4a3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764554700,
      "headline": "2 Undervalued, High-Quality Companies to Buy Now and Hold Forever",
      "id": 137650213,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "If you are looking to own a stock for the long term, these out-of-favor drugmakers have proven they have what it takes to survive.",
      "url": "https://finnhub.io/api/news?id=15560fee524920002e1518664dcc0ea6c8ab46fe1c923913fd80fd84f81ec4a3"
    }
  },
  {
    "ts": null,
    "headline": "BioNTech (BNTX) Is Up 7.9% After Raising 2025 Revenue Guidance on Bristol-Myers Collaboration",
    "summary": "In late November, BioNTech raised its full-year 2025 revenue guidance, recognizing US$700 million from its collaboration with Bristol-Myers Squibb, while reporting a net loss for the quarter due to a contractual dispute and continuing investments to transition into a commercial oncology company. An important development from this period is BioNTech’s accelerated clinical advancement, highlighted by ongoing Phase III trials in lung and triple-negative breast cancers and the outlined timeline...",
    "url": "https://finnhub.io/api/news?id=c408d9b4c507e2bcd039bbfc09c22aaf6baeac794959070dc1248074694767b9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1764548199,
      "headline": "BioNTech (BNTX) Is Up 7.9% After Raising 2025 Revenue Guidance on Bristol-Myers Collaboration",
      "id": 137650338,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BMY",
      "source": "Yahoo",
      "summary": "In late November, BioNTech raised its full-year 2025 revenue guidance, recognizing US$700 million from its collaboration with Bristol-Myers Squibb, while reporting a net loss for the quarter due to a contractual dispute and continuing investments to transition into a commercial oncology company. An important development from this period is BioNTech’s accelerated clinical advancement, highlighted by ongoing Phase III trials in lung and triple-negative breast cancers and the outlined timeline...",
      "url": "https://finnhub.io/api/news?id=c408d9b4c507e2bcd039bbfc09c22aaf6baeac794959070dc1248074694767b9"
    }
  }
]